Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Submission has been made for review under the accelerated approval pathway LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc....